Serhat SAYIN, Ethem ÖMEROĞLU, Semra ASLAN BİLGİN

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system. It has moderate glycemic efficacy, a low propensity of causing hypoglycaemia and it is weight neutral. Overall, Dipeptidyl peptidase-4 (DPP-4) inhibitors are well tolerated. The use of DPP-4 inhibitors has been associated with a slightly increased risk of upper respiratory tract infections. In this article, we report a case of cutaneous leukocytoclastic vasculitis due to probable vildagliptin usage. Vildagliptin which is associated with cutaneous leukocytoclastic vasculitis was not described in the literature before. Physical examination revealed skin rash in the abdomen and thigh region in our patients due to use of the drug. Discontinuation of the drug eliminated the skin rash immediately.

PDF

___

Nauck MA, Vilsøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32:223-31.

Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775–83.

Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–15.

Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–9.

Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab. 2009;11(Suppl 2):9–17.

Koutkia P, Mylonakis E, Rounds S, Erickson A. Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol. 2001;30(6):315-22.

Sais G, Vidaller A, Jucglà A, Servitje O, Condom E, Peyri J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134(3):309-15.

Lotti T, Ghersetich I, Comacchi C, Jorizzo JL. Cutaneous smallvessel vasculitis. J Am Acad Dermatol. 1998;39(5 Pt 1):667-87.

Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45(1):3-13.

Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56(1):3-23.

Merker PA. Drug induced vasculitis. Rheum Dis Clin North Am. 2001;27(4):849-62.

Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420-34.

Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127(4):515-22.

Turner AN, Whittaker S, Banks I, Jones RR, Pusey CD. Plasma exchange in refractory cutaneous vasculitis. Br J Dermatol. 1990;122(3):411-5.